Divi's Laboratories Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
9,634
- Stock Symbol
-
DIVISLAB
- Share Price
-
$119.59
- (As of Thursday Closing)
Divi's Laboratories General Information
Description
Divi's Laboratories Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical Ingredients, with predominance in exports. Through its custom synthesis business, the Company supports innovator pharma companies for patented products from gram-scale requirements for clinical trials to launch and late-life cycle management, in addition to generics. It operates in a single operating segment, Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceutical Ingredients. The Company derives maximum revenue from Europe.
Contact Information
Website
www.divislabs.comCorporate Office
- Divi Towers, Cyber Hills
- Gachibowli
- Hyderabad, 500032
- India
Corporate Office
- Divi Towers, Cyber Hills
- Gachibowli
- Hyderabad, 500032
- India
Divi's Laboratories Stock Performance
As of 19-Nov-2026, Divi's Laboratories’s stock price is $119.59. Its current market cap is $31.7B with 265M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $119.59 | $118.20 | $60.96 - $125.90 | $31.7B | 265M | 630K | $1.37 |
Divi's Laboratories Financials Summary
As of 30-Sep-2026, Divi's Laboratories has a trailing 12-month revenue of $1.31B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 25,343,893 | 16,321,103 | 17,471,189 | 10,538,039 |
| Revenue | 1,314,833 | 1,185,554 | 1,102,804 | 941,707 |
| EBITDA | 536,244 | 406,275 | 357,746 | 270,940 |
| Net Income | 362,709 | 290,617 | 259,114 | 193,270 |
| Total Assets | 2,286,697 | 2,123,206 | 1,979,441 | 1,855,061 |
| Total Debt | 625 | 742 | 468 | 360 |
Divi's Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Divi's Laboratories Comparisons
Industry
Financing
Details
Divi's Laboratories Competitors (15)
One of Divi's Laboratories’s 15 competitors is Zydus Lifesciences, a Corporation company based in Ahmedabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zydus Lifesciences | Corporation | Ahmedabad, India | ||||
| Aurobindo Pharma | Corporation | Hyderabad, India | ||||
| Wockhardt | Corporation | Mumbai, India | ||||
| Anthem Biosciences | Formerly PE-Backed | Bengaluru, India | ||||
| Sun Pharmaceutical Industries | Corporation | Mumbai, India |
Divi's Laboratories Patents
Divi's Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4763856-A1 | Process for the preparation of fmoc-gly-thr [psi (me, me) pro]-oh | Pending | 17-Dec-2024 | ||
| US-20260167668-A1 | Process for the preparation of fmoc-gly-thr [psi (me, me) pro]-oh | Pending | 17-Dec-2024 | ||
| EP-4282971-A1 | An improved process for the preparation of (r )-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam | Pending | 23-May-2022 | ||
| JP-7402935-B2 | An improved process for the preparation of (r)-4-propylpyrrolidin-2-one, a key intermediate for the synthesis of brivaracetam. | Active | 23-May-2022 | ||
| JP-2023172821-A | Improved process for preparation of (r)-4-propyl pyrrolidine-2-one, key intermediate for synthesis of brivaracetam | Active | 23-May-2022 | C12P7/62 |
Divi's Laboratories Signals
Divi's Laboratories Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Divi's Laboratories ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
31.25 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Divi's Laboratories FAQs
-
When was Divi's Laboratories founded?
Divi's Laboratories was founded in 1990.
-
Where is Divi's Laboratories headquartered?
Divi's Laboratories is headquartered in Hyderabad, India.
-
What is the size of Divi's Laboratories?
Divi's Laboratories has 9,634 total employees.
-
What industry is Divi's Laboratories in?
Divi's Laboratories’s primary industry is Drug Discovery.
-
Is Divi's Laboratories a private or public company?
Divi's Laboratories is a Public company.
-
What is Divi's Laboratories’s stock symbol?
The ticker symbol for Divi's Laboratories is DIVISLAB.
-
What is the current stock price of Divi's Laboratories?
As of 19-Nov-2026 the stock price of Divi's Laboratories is $119.59.
-
What is the current market cap of Divi's Laboratories?
The current market capitalization of Divi's Laboratories is $31.7B.
-
What is Divi's Laboratories’s current revenue?
The trailing twelve month revenue for Divi's Laboratories is $1.31B.
-
Who are Divi's Laboratories’s competitors?
Zydus Lifesciences, Aurobindo Pharma, Wockhardt, Anthem Biosciences, and Sun Pharmaceutical Industries are some of the 15 competitors of Divi's Laboratories.
-
What is Divi's Laboratories’s annual earnings per share (EPS)?
Divi's Laboratories’s EPS for 12 months was $1.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process